Skip to main content

Table 1 Patients’ medical history

From: COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

 COVID-19 patients, N pts/N evaluable (%)RNA-positive subgroup, N pts/N evaluable (%)
Patient characteristics
 Median age (IQR)58 (48–68)57 (48–68)
 Median BMI (IQR)26 (22–30)26 (22–29)
 Comorbidities
  Age > 70 years old10/59 (17%)8/41 (20%)
  Obesity (BMI > 30)10/59 (17%)7/41 (17%)
  Active smokers4/59 (7%)3/41 (7%)
  Chronic lung disease2/59 (3%)1/41 (2%)
  Diabetes10/59 (17%)9/41 (22%)
  Hypertension21/59 (36%)17/41 (42%)
  Heart disease8/59 (14%)8/41 (20%)
  Systemic disease3/59 (5%)3/41 (7%)
  Any of the above20/59 (34%)13/41 (32%)
 Comedications
  Corticosteroids13/59 (22%)9/41 (22%)
  NSAID0/59 (0%)0/41 (0%)
  ACE inhibitor/ARB15/59 (25%)13/41 (32%)
  Anticoagulants8/59 (14%)5/41 (12%)
  Immunosuppressives1/59 (2%)1/41 (2%)
Breast cancer
 Subtype
  HR+39/59 (66%)29/41 (70%)
  Triple-negative10/59 (17%)6/41 (15%)
  HER2+10/59 (17%)6/41 (15%)
 Clinical setting
  Neoadjuvant7/59 (12%)7/41 (17%)
  Adjuvant15/59 (25%)15/41 (37%)
  Metastatic, < 3 prior lines20/59 (34%)11/41 (27%)
  Metastatic, ≥ 3 prior lines17/59 (29%)8/41 (20%)
 History of radiation therapy
  Breast/chest wall irradiation36/59 (61%)19/41 (46%)
  SCLN irradiation29/59 (49%)14/41 (34%)
  IMN irradiation23/59 (39%)11/41 (27%)
  None23/59 (39%)22/41 (54%)
 Metastatic sites (in metastatic pts)
  < 3 sites22/37 (60%)14/19 (74%)
  ≥ 3 sites15/37 (41%)5/19 (26%)
  Lung/pleural metastases16/37 (43%)5/19 (26%)
  Bone metastases24/37 (65%)17/19 (90%)
  Liver metastases11/37 (30%)5/19 (26%)
  CNS metastases7/37 (19%)3/19 (16%)
  Other sites16/37 (43%)7/19 (37%)
TotalN = 59N = 41
  1. Corticosteroids refer to a chronic daily dose equivalent to ≥ 20 mg of prednisolone (chemotherapy premedication not taken into account). Systemic diseases: 2 patients had a rheumatoid arthritis and 1 patient had an autoimmune hepatitis. BMI body mass index, NSAID non-steroidal anti-inflammatory drugs, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers, HR+ hormone receptor-positive, Triple-negative HER2- and hormone receptor-negative, HER2+ HER2-positive, CNS central nervous system, SCLN supraclavicular lymph nodes, IMN internal mammary nodes